274 related articles for article (PubMed ID: 30600304)
1. The Evolving Role of Liver Biopsy in Non-alcoholic Fatty Liver Disease.
Arab JP; Barrera F; Arrese M
Ann Hepatol; 2018 Oct; 17(6):899-902. PubMed ID: 30600304
[TBL] [Abstract][Full Text] [Related]
2. Role of liver biopsy in nonalcoholic fatty liver disease.
Nalbantoglu IL; Brunt EM
World J Gastroenterol; 2014 Jul; 20(27):9026-37. PubMed ID: 25083076
[TBL] [Abstract][Full Text] [Related]
3. The role of noninvasive tests and liver biopsy in the diagnosis of nonalcoholic fatty liver disease.
Isabela Andronescu C; Roxana Purcarea M; Aurel Babes P
J Med Life; 2018; 11(3):243-246. PubMed ID: 30364513
[TBL] [Abstract][Full Text] [Related]
4. AGA Clinical Practice Update on the Role of Noninvasive Biomarkers in the Evaluation and Management of Nonalcoholic Fatty Liver Disease: Expert Review.
Wattacheril JJ; Abdelmalek MF; Lim JK; Sanyal AJ
Gastroenterology; 2023 Oct; 165(4):1080-1088. PubMed ID: 37542503
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis.
Younossi ZM; Loomba R; Anstee QM; Rinella ME; Bugianesi E; Marchesini G; Neuschwander-Tetri BA; Serfaty L; Negro F; Caldwell SH; Ratziu V; Corey KE; Friedman SL; Abdelmalek MF; Harrison SA; Sanyal AJ; Lavine JE; Mathurin P; Charlton MR; Goodman ZD; Chalasani NP; Kowdley KV; George J; Lindor K
Hepatology; 2018 Jul; 68(1):349-360. PubMed ID: 29222917
[TBL] [Abstract][Full Text] [Related]
6. Liver fibrosis markers of nonalcoholic steatohepatitis.
Enomoto H; Bando Y; Nakamura H; Nishiguchi S; Koga M
World J Gastroenterol; 2015 Jun; 21(24):7427-35. PubMed ID: 26139988
[TBL] [Abstract][Full Text] [Related]
7. Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease.
Castera L; Friedrich-Rust M; Loomba R
Gastroenterology; 2019 Apr; 156(5):1264-1281.e4. PubMed ID: 30660725
[TBL] [Abstract][Full Text] [Related]
8. Biopsy and Noninvasive Methods to Assess Progression of Nonalcoholic Fatty Liver Disease.
Bedossa P; Patel K
Gastroenterology; 2016 Jun; 150(8):1811-1822.e4. PubMed ID: 27003601
[TBL] [Abstract][Full Text] [Related]
9. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y; Fukusato T
World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438
[TBL] [Abstract][Full Text] [Related]
10. Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography.
Imajo K; Kessoku T; Honda Y; Tomeno W; Ogawa Y; Mawatari H; Fujita K; Yoneda M; Taguri M; Hyogo H; Sumida Y; Ono M; Eguchi Y; Inoue T; Yamanaka T; Wada K; Saito S; Nakajima A
Gastroenterology; 2016 Mar; 150(3):626-637.e7. PubMed ID: 26677985
[TBL] [Abstract][Full Text] [Related]
11. Fibrosis Assessment in Nonalcoholic Fatty Liver Disease (NAFLD) in 2016.
Kaswala DH; Lai M; Afdhal NH
Dig Dis Sci; 2016 May; 61(5):1356-64. PubMed ID: 27017224
[TBL] [Abstract][Full Text] [Related]
12. Bedside ultrasound in the diagnosis of nonalcoholic fatty liver disease.
Khov N; Sharma A; Riley TR
World J Gastroenterol; 2014 Jun; 20(22):6821-5. PubMed ID: 24944472
[TBL] [Abstract][Full Text] [Related]
13. Histopathological Diagnosis of Nonalcoholic Steatohepatitis (NASH).
Giashuddin S; Alawad M
Methods Mol Biol; 2022; 2455():1-18. PubMed ID: 35212981
[TBL] [Abstract][Full Text] [Related]
14. Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study.
Rastogi A; Shasthry SM; Agarwal A; Bihari C; Jain P; Jindal A; Sarin S
APMIS; 2017 Nov; 125(11):962-973. PubMed ID: 29076589
[TBL] [Abstract][Full Text] [Related]
15. Clinical relevance of liver histopathology and different histological classifications of NASH in adults.
Nascimbeni F; Ballestri S; Machado MV; Mantovani A; Cortez-Pinto H; Targher G; Lonardo A
Expert Rev Gastroenterol Hepatol; 2018 Apr; 12(4):351-367. PubMed ID: 29224471
[TBL] [Abstract][Full Text] [Related]
16. Biopsy rate and nonalcoholic steatohepatitis (NASH) in patients with nonalcoholic fatty liver disease (NAFLD).
Gerhardt F; Petroff D; Blank V; Böhlig A; van Bömmel F; Wittekind C; Berg T; Karlas T; Wiegand J
Scand J Gastroenterol; 2020 Jun; 55(6):706-711. PubMed ID: 32476514
[No Abstract] [Full Text] [Related]
17. Noninvasive Evaluation of Nonalcoholic Fatty Liver Disease.
Castera L
Semin Liver Dis; 2015 Aug; 35(3):291-303. PubMed ID: 26378645
[TBL] [Abstract][Full Text] [Related]
18. Serum cytokeratin-18 fragment levels as noninvasive marker of nonalcoholic steatohepatitis in the chilean population.
Arab JP; Hernández-Rocha C; Morales C; Vargas JI; Solís N; Pizarro M; Robles C; Sandoval D; Ponthus S; Benítez C; Barrera F; Soza A; Riquelme A; Arrese M
Gastroenterol Hepatol; 2017; 40(6):388-394. PubMed ID: 28359548
[TBL] [Abstract][Full Text] [Related]
19. Diagnosis and Evaluation of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Noninvasive Biomarkers and Transient Elastography.
Tsai E; Lee TP
Clin Liver Dis; 2018 Feb; 22(1):73-92. PubMed ID: 29128062
[TBL] [Abstract][Full Text] [Related]
20. The use of current knowledge and non-invasive testing modalities for predicting at-risk non-alcoholic steatohepatitis and assessing fibrosis.
Kugelmas M; Noureddin M; Gunn N; Brown K; Younossi Z; Abdelmalek M; Alkhouri N
Liver Int; 2023 May; 43(5):964-974. PubMed ID: 36864668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
